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Inhalation therapy during acute asthma
The role of a combined steroid and beta-stimulant preparation
J. R. JOUBERT, G. BURGER, E. SHEPHARD
Summary
A compound consisting of aB-stimulant, salbutamol
(Ventolin; Alien & Hanburys) (100 JIg I puff), and a
steroid, beclomethasone dipropionate (Becotide; Alien
& Hanburys) (50 JIg I puff), was studied to test the
hypothesis that the corticosteroid could enhance the
bronchodilator properties of the B-stimulant during
chronic asthma and simulated acute attacks (antigen
challenge). Conventional doses (200 JIg and 100 JIg
of salbutamol and beclomethasone respectively) were
compared using a schedule which included a second
administration 1 hour later. The results obtained on
the baseline bronchial responsiveness of chronic
asthmatics and during the delayed asthmatic
response (simulated acute asthma) were similar. The
compound was as effective as salbutamol alone but
not more so. A significantly greater bronchodilator
response was recorded in all patients after the second
administration of both the compound and salbutamol
alone. The practical advantages of having one rather
than two inhalers are evident, but the appropriate
application of this compound agent, probably in a
prophylactic role, must be defined.
S AIr Med J 1985; 68: 381-384.
The latest development in the treatment of acute prolonged
asthma (APA) has been the addition of inhaled salbutamol
(Ventolin; AlIen & Hanburys) as an alternative or adjunct to
intravenous bronchodilator therapy.I,2 The role of this agent,
and possible alternative forms of inhalation therapy in con-
ventional regimens during APA, have yet to be established.
Drug trials conducted during APA are subject to a number of
variables which make interpretation of the results extremely
difficult. These include the degree of asthmatic obstruction,
which in turn depends upon a variety of contributing factors,
e.g. mucus plugs, infection, airways oedema and muscle spasm.
In addition corticosteroids, an essential component of therapy,
constitute a factor which influences the efficacy of broncho-
dilator agents. 3,4
This study was planned to circumvent these problems and
to test a compound which contains salbutamol, a R-stimulant
(100 JIg/puff), and the steroid beclomethasone dipropionate
(BDP) (Becotide; AlIen & Hanburys) (50 JIg/puff) under
conditions of acute and chronic asthma. The compound has
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been found to be as potent as the active components admini-
stered individually for control of clinical asthma in outpatients.5
Studies during APA with this agent have, however, not been
reported. The delayed asthmatic response (DAR) which occurs
3 - 5 hours after inhalation challenge with antigen represents
the closest model of APA which can be induced reproducibly
with a minimum of uncontrolled variables. 6•7 It differs from
the early asthmatic response (EAR) in terms of response to
inhaled R-stimulant and corticosteroid treatment. Cortico-
steroids inhaled before antigen challenge suppress DAR but
not EAR. 8,9 Beta-stimulants can prevent or suppress EAR, but
doubt exists as to their bronchodilating properties during
DAR. Hexoprenaline administered during DAR induces a
temporary and incomplete reversal of airways obstruction,
which lasts for less than an hour, and isoprenaline is similarly
ineffective.9- 11
No studies have as yet been conducted to determine the
effectiveness of corticosteroids alone or in combination with
R-stimulants in reversing DAR. A study of this nature could
be of value in determining how effective self-treatment with a
nebulizer specifically containing a compound is in terminating
APA. For this purpose the active agent salbutamol, BDP as
well as salbutamol and the compound were administered
separately during DAR to determine which agent or combina-
tion of agents would be most effective in terminating this
phase of the asthmatic reaction. A similar protocol was followed
in 5 stable chronic asthmatics. The degree and duration of
bronchodilatation induced by the combinations of drugs was
compared.
It has recently been reported that controlled administration
of increasing amounts of salbutamol can determine the
magnitude of bronchodilatation. 12 The possibility that con-
ventionally prescribed doses may be too low for terminating an
acute asthmatic attack therefore exists. A study of the influence
of drug dosage administered by nebulizers in reversing DAR
in naturally occurring asthma suggests that underusage rather
than abuse prevails when patients attempt to reverse chronic
or acute asthma with a commonly prescribed dose of broncho-
dilator agents. The new compound may have practical
advantages for patients who require R-stimulant and cortico-
steroid agents for long-term prophylaxis. No evidence was
found, however, that it is more effective than salbutamol alone
for reversing the acute asthmatic response.
Patients and methods
A small group of asthmatic patients was included in one of two
double-blind crossover studies. For both studies identical-
looking inhalers were provided which delivered in each metered
dose either: (I) 100 JIg salbutamol with 50 JIg BDP or (il) 100
JIg salbutamol or (iil) 50 JIg BDP or (iv) placebo (freons and
surfactant only).
On each occasion the patients were asked to take two
inhalations from each of a pair of inhalers. The treatment
schedule was the same for both studies and on 6 test days the
patients received in random order the following inhalers: (I)
placebo + placebo; (il) combination + placebo; (iil) salbutamol
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+ BDP; (iV) salbutamol + placebo, repeated at I hour; (v)
combination + placebo, repeated at 1 hour; and (V!) salbutamol
+ BDP, repeated at 1 hour.
Study 1
Chronic asthmatic patients were eligible to enter this study
provided they had previously documented evidence of at least
20% variability of their airways obstruction. There were 3
males and 2 females, aged from 13 - 53 years, with atopic
asthma as defined by history, skin tests and reversibility of
airways obstruction. All were non-smokers, all required
bronchodilator therapy, and I patient was receiving treatment
with inhaled corticosteroids. Patients were instructed to cease
their treatment 12 hours before study days.
After arriving at the laboratory on each occasion a baseline
flow-volume curve was obtained. Patients performed this
manoeuvre on a Collins dry seal spirometer until two identical
curves were measured. The area below the flow-volume curve
was determined electronically and was employed to determine
the post-therapy and antigen challenge bronchial response.
Care was taken to obtain the best standard baseline value for
each individual on every study day and a mean variation of
16% between study days was recorded (the smallest individual
variation being 7%, the largest 29%). The appropriate two
inhalers were selected for each of the occasions, which were on
successive days where possible and no further than 7 -14 days
apart. The flow-volume curve was repeated at IS minutes and
I hour after inhalation. According to the randomization code,
on 3 test days the flow-volume curve was repeated at hourly
intervals until 6 hours. On the other 3 test days a second dose
(two puffs) from both inhalers was given I hour after the first
treatment and the measurements repeated after a further 15
minutes, at 1 hour, and then at each hour until 8 hours (Fig.
I).
Study 2
Patients in this group'were antigen challenged and the drugs
.administered during DAR. Atopic asthmatic patients who had
previously been shown to have a dual asthmatic response
following a specific antigen challenge were eligible to enter the
study. The specific antigen had been identified by skin-testing
and the challenge dose that produced both an immediate and
late reaction had previously been identified for each patient.
This proved to be house dust mite in 4 and grass pollen in I
patient. Solutions of 1: 5 000 - I : 10000 for 2 - 4 minutes were
employed for inhalation challenge. It was important to note
that none of the patients was taking oral or inhaled cortico-
steroids during the week before each study day. Suitable
patients were asked to anend the laboratory at 1 - 3-week
intervals on 6 occasions, having withheld all asthma therapy
for 12 hours before the start of each test day.
After arrival on each day, a baseline flow-volume curve was
obtained and then the provocation test was performed. For
each patient the concentration of antigen, rate of breathing
and duration of nebulization were kept the same on all 6
occasions. A flow-volume curve was repeated initially at 15-
minute intervals for the first hour and a half to identify the
immediate response and then at hourly intervals.
The occurrence of DAR was considered established when,
after recovery from the immediate response, the area under
the flow-volume curve fell again at 2 time points. The
appropriate two inhalers were then selected and administered
during DAR by asking the patient to take two inhalations from
both. On 3 test days, as determined by the randomization
code, the flow-volume curve was then repeated after IS minutes,
1, 2 and 3 hours. On the other 3 test days the flow-volume
curve was repeated at IS minutes and I hour, then a second
dose was administered from both inhalers and the flow-
volume curve repeated again after a further IS minutes, I, 2
and 3 hours (Fig. 2).
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Fig. 1. The effect of different therapies on the bronchial response in chronic asthmatic patients. A - response to a single dose
of the agent; and B - response to a second dose 1 hour after the first dose (indicated by arrow). Each point represents the
change in the pre-challenge flow-volume curve value expressed as a percentage of the pre-challenge value (ll, N = 5), at
various time points (e--e placebo; x--x compound; e --- e salbutamol and SDP; @--@salbutamol).
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Fig. 2. The effect of different agents on the bronchial response to the delayed antigen-induced asthmatic reaction. For purposes of
simplification the early asthmatic points were excluded and only two measurements at hourly intervals preceding drug administra-
tion are shown. A - response following a single dose of therapy and S - response following a second dose of therapy 1 hour
after the first dose. Arrows indicate time points at which a single dose of therapy was administered. Each point represents the
change in the pre-challenge flow-volume curve value expressed as a percentage of the pre-challenge value (X, N = 5), at various
time points (. --. placebo; x --x compound; • ---- • salbutamol and SDP; @}--@ salbutamol).
Results
Five asthmatic patients entered and completed each of the
studies.
Study 1
The mean response curve for each test day has been plotted
in Fig. 1. The mean predicted normal area under the flow-
volume curve for the non-challenged chronic asthmatic group
was 11,13 12/s and a change of 15% (or 1,7 Pis) in the area
under the curve was considered significant. At I hour, all 5
active treatments produced a similar bronchodilator response
which was always significantly greater than after the placebo
"(Fig. lA and B). The pl1!cebo results were excluded from
further statistical analysis of the data, since the pattern of
response to placebo administration differed markedly from the
response seen after treatment. In all cases, P MEAN (placebo)
was less than 1,0, while P MEAN (active treatments) was greater
than 1,0 at every point of observation. At 2 houts, both single-
dose treatments were better than placebo and there was no
difference in the response achieved with the combination
inhaler or the two separate inhalers of salbutamol and BDP
(Fig. lA). At 6 .hours there was no difference in the residual
response between placebo and the combination inhaler. The
effect of the two separate inhalers appeared to be more pro-
longed than that of the combination preparatiQil at 6 hours,
but this difference was not bOfIle out by the overall response
achieved by the two active treatments.
On the 3 days when a second dose was administered at I
hour, there was no difference in the bronchodilator response
induced by the three forms of active therapy during the
subsequent 6-hour follow-up period (Fig. IB); however, when
comparing the single-dose and double-dose treatments, signifi-
cantly greater bronchodilation was achieved at 2 and 3 hours
on the days when a second dose was given (P = 0,05;
Wilcoxon matched-pair signed-rank test). This was true for all
active preparations or combinations tested. As regards the
residual response at 6 and 7 hours on the days after second
doses had "been given, the true treatments are equivalent.
However, when comparing the area under the flow-volume
curve at 6 hours on days when second doses were given with
that of similar treatments at the same time on single-qose
days, a trend was seen towards prolongation of bronchodilation
by the second dose. This benefit was most marked with the
combination inhaler (Fig. IB).
Group 2
The mean values for the area under the flow-volume curves
ranged from 5,04 to 6,66 before treatment, from 8,60 to 10,04
I hour after active treatment and from 7,04 to 9,78 at the end
of the study for the active treatment groups.
Comparison of the mean incremental response at I hour
after treatment showed no significant differences between the
5 active treatments (Fig. 2A and B). At all time points after
treatment the single-dose active treatments were better than
placebo (Fig. 2A). At 3 time points after the second dose, a
prolongation of effect was seen with all 3 treatments; this was
most marked with the combination inhaler (P = 0,05). These
values indicate that enhanced and prolonged bronchodilation
was achieved during DAR by the double-dose regimens of all
three active agents. No statistical difference was perceived
between the results of double doses of the 3 active agents
during DAR.
Discussion
The rationale for employing the compound in an acute asth-
matic attack relates to the enhancing effect of corticosteroids
on B-receptor sensitivity to administered B-stimulants. In vitro
evidence has been found for higher levels of 3', 5'-cyclic
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adenosine monophosphate, an inherent. component of the R-
receptor, being produced during corticosteroid administration. 13
Self-treatment with the combination in an acceptable form
could be of great value to asthmatics whose acute anacks occur
at night or when far from medical assistance.
In a study in which inhalation preparations were employed
for reversal of DAR, ]oubert lO showed that inhaled cortico-
steroids enhanced the weak bronchodilating properties.of hexo-
prenaline and theophylline. In the present study the efficacy
of the combined agent during simulated acute asthma and
chronic airways obstruction related to the bronchodilating
action of salbutamol.
The age range of patients was wide but particular care was
taken to exclude chronic bronchitis so that the bronchodilating
effect indicated reversal of an asthmatic mechanism. Because
of the amount of work involved specifically for repeated
antigen challenge, results were obtained on a relatively small
group of patients. This weakness in the study is offset by
identical results in all subjects, which suggests that a larger
study would lead to similar conclusions. No effect of the
inhaled steriod agent on either the degree of responsiveness to
the R-stimulant or duration thereof was clearly demonstrated.
A possible reason for the findings of the present study relates
to the potency of the R-stimulant.
Our results suggest that during the early phases of an acute
asthmatic anack, B-receptor enhancement by corticosteroids
does not play an important role if a highly effective agent such
as salbutamol is used for bronchodilation. An important proviso
for the success of B-stimulant inhalation therapy would be, in
practice, that the patient should recognize early signs of onset
of an acute anack of asthma. Prolonged periods of broncho-
constriction with subsequent mucous plug formation and
oedema of the mucosa could substantially decrease the
bronchodilator response to inhaled agents.
Patients frequently question their practitioners about the
long-term safety of inhaled R-stimulant agents. Studies in
which unexpected deaths related to alleged overdosage of
isoproterenol are cited. '4 Clear evidence was found in this
study that in naturally occurring asthma as well as the antigen-
induced DAR, salbutamol in the conventional dose of 200 j.Lg
does not completely restore optimal airway patency. Improve-
ment after a second dose of 200 j.Lg was recorded with either
the salbutamol alone or the combined preparation. Spector
and Gomez l5 compared the effect of different doses of
salbutamol and showed that a maximum dose of 680 j.Lg caused
the greatest improvement in lung function in chronic
asthmatics. No increase in side-effects was noted. This was
borne out by the greater degree of bronchodilation achieved
when a second dose of 200 j.Lg was administered at 1 hour
either in the form of the compound or as individual sub-
components of the combination preparation. Patients can there-
fore be safely advised to use their salbutamol nebulizers
repeatedly at 10 - IS-minute intervals in double the conventional
doses over a period of 60 - 90 minutes. If the symptoms of
airflow obstruction persist or tend to recur, medical advice
should be sought.
As there exists no way of finding the exact combination of
factors which cause airway obstruction at any given moment in
any specific patient, an acute and a chronic model of asthma
were employed. Clark and Anderson l6 have shown that
prophylactic use of BDP and salbutamol clearly improves
long-term lung function of chronic asthmatics. In the present
short-term study of a group of chronic asthmatics the thera-
peutic response was similar when nebulizers containing'
individual agents were employed or when the combined agent
was inhaled as a single preparation. Although the bio-availability
of the steroid component was not established, the activity of
salbutamol in a combined preparation was demonstrated. We
believe that a test of this agent for its prophylactic properties
in chronic asthmatics should be carried out. Should it prove to
be as effective as the two separate agents, it would afford the
asthmatic the practical advantage of using a single inhaler and
might improve patient compliance with inhalation treatment.
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